Globus Medical Announces $500 Million Share Repurchase Program
Globus Medical (NYSE: GMED) has announced a significant $500 million share repurchase program of its outstanding common stock. The company's management believes there is a disconnect between their intrinsic value and current market valuation due to recent share price volatility.
The program will be funded through cash reserves and has no time limit. The actual implementation will be at management's discretion, considering factors such as market price, business conditions, legal requirements, and alternative investment opportunities. The repurchases may be executed through private negotiations or open market transactions, including under Rule 10b5-1 and Rule 10b-18.
Globus Medical (NYSE: GMED) ha annunciato un importante programma di riacquisto di azioni per 500 milioni di dollari delle proprie azioni ordinarie in circolazione. La direzione dell'azienda ritiene che esista una discrepanza tra il valore intrinseco e la valutazione attuale di mercato a causa della recente volatilità del prezzo delle azioni.
Il programma sarà finanziato tramite riserve di liquidità e non ha una scadenza temporale. L'attuazione effettiva sarà a discrezione della direzione, che terrà conto di fattori quali il prezzo di mercato, le condizioni aziendali, i requisiti legali e le opportunità di investimento alternative. I riacquisti potranno essere effettuati tramite negoziazioni private o transazioni sul mercato aperto, inclusi gli strumenti previsti dalle regole 10b5-1 e 10b-18.
Globus Medical (NYSE: GMED) ha anunciado un importante programa de recompra de acciones por 500 millones de dólares de sus acciones ordinarias en circulación. La dirección de la empresa considera que existe una desconexión entre su valor intrínseco y la valoración actual del mercado debido a la reciente volatilidad en el precio de las acciones.
El programa se financiará con reservas de efectivo y no tiene un límite temporal. La implementación real será a discreción de la dirección, considerando factores como el precio de mercado, las condiciones comerciales, los requisitos legales y las oportunidades de inversión alternativas. Las recompras podrán realizarse mediante negociaciones privadas o transacciones en el mercado abierto, incluyendo bajo las reglas 10b5-1 y 10b-18.
글로버스 메디컬(NYSE: GMED)은 자사 보통주의 5억 달러 규모 주식 재매입 프로그램을 발표했습니다. 경영진은 최근 주가 변동성으로 인해 내재 가치와 현재 시장 평가 간에 괴리가 있다고 판단하고 있습니다.
본 프로그램은 현금 보유고를 통해 자금을 조달하며, 기간 제한이 없습니다. 실제 실행은 시장 가격, 사업 상황, 법적 요건 및 대체 투자 기회 등의 요소를 고려하여 경영진 재량에 따라 결정됩니다. 재매입은 비공개 협상 또는 공개 시장 거래를 통해 이루어질 수 있으며, Rule 10b5-1 및 Rule 10b-18 규정을 포함합니다.
Globus Medical (NYSE : GMED) a annoncé un important programme de rachat d’actions d’une valeur de 500 millions de dollars de ses actions ordinaires en circulation. La direction de l’entreprise estime qu’il existe un décalage entre la valeur intrinsèque de ses actions et leur valorisation actuelle sur le marché, en raison de la volatilité récente du cours.
Le programme sera financé par les réserves de trésorerie et n’a pas de limite temporelle. Sa mise en œuvre effective sera à la discrétion de la direction, qui tiendra compte de facteurs tels que le prix du marché, les conditions commerciales, les exigences légales et les opportunités d’investissement alternatives. Les rachats pourront s’effectuer par des négociations privées ou des transactions sur le marché ouvert, y compris sous les règles 10b5-1 et 10b-18.
Globus Medical (NYSE: GMED) hat ein bedeutendes Aktienrückkaufprogramm in Höhe von 500 Millionen US-Dollar für seine ausstehenden Stammaktien angekündigt. Das Management des Unternehmens ist der Ansicht, dass eine Diskrepanz zwischen dem inneren Wert und der aktuellen Marktbewertung aufgrund der jüngsten Kursvolatilität besteht.
Das Programm wird aus liquiden Mitteln finanziert und ist zeitlich unbegrenzt. Die tatsächliche Umsetzung erfolgt nach Ermessen des Managements unter Berücksichtigung von Faktoren wie Marktpreis, Geschäftslage, rechtlichen Anforderungen und alternativen Investitionsmöglichkeiten. Die Rückkäufe können durch private Verhandlungen oder offene Markttransaktionen erfolgen, einschließlich nach Rule 10b5-1 und Rule 10b-18.
- Authorization of substantial $500 million share repurchase program indicates strong confidence in company's future
- Program to be funded through existing cash reserves, demonstrating solid financial position
- Flexible implementation with no time limit allows strategic execution
- Management sees current stock as undervalued, suggesting potential upside
- Share repurchase reduces cash available for business operations and growth investments
- No guarantee of stock price appreciation despite buyback program
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to
“We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation,” said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. “Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforces our commitment to delivering long-term value to our shareholders.”
The timing and actual number of shares repurchased will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities. The repurchase program will be executed consistent with the company’s capital allocation strategy of prioritizing investment to grow the business over the long term.
Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. The Company intends to utilize its cash reserves to fund the share repurchase program.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of Globus Medical contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
(610) 930-1800
investors@globusmedical.com
www.globusmedical.com
Media contact:
Moran Chavez
media@globusmedical.com
FAQ
What is the size of Globus Medical's (GMED) new share repurchase program?
How will Globus Medical fund the GMED stock buyback program?
Is there a time limit for Globus Medical's share repurchase program?
Why did Globus Medical announce a stock buyback program in May 2025?
How will GMED execute its share repurchase program?
